Patients with high-risk stage III-IV melanoma who received Keytruda (pembrolizumab) after surgery reported a better quality of life than patients who received the previous standard-of-care treatment with either ipilimumab or high-dose interferon, according to a large clinical trial led by the SWOG Cancer Research Network.
Salk Institute scientists discovered a relationship between killer T-cell exhaustion and the body’s sympathetic stress response, or “fight-or-flight,” in varying cancer types in mouse and human tissue samples.
